卵巢癌中雷公藤内脂醇的研究进展

卵巢癌是严重威胁女性生殖健康的肿瘤之一，死亡率居各类妇科肿瘤的首位。多药耐药是治疗后复发、转移甚至死亡的主要原因。雷公藤内酯醇（triptolide，TP）具有很强的抗肿瘤活性，其在卵巢癌治疗方面的作用也引起了众多学者的重视，尤其是在多药耐药卵巢癌治疗中的应用。本文从抑制卵巢癌细胞增殖、诱导癌细胞凋亡两大方面综述雷公藤内酯醇在卵巢癌治疗中的研究进展。TP的毒性反应、半衰期短等缺点限制了其临床应用，纳米给药技术的出现为TP用于卵巢癌治疗提供了更广阔的应用前景。

Progress of Triptolide in Ovarian Cancer

Ovarian cancer is a serious threat to women′s reproductive health, and the mortality is the first of various gynecological tumors. Multidrug resistance(MDR) is a major cause of post-treatment relapses, metastasis, and even death. The role of triptolide(TP) in the treatment of ovarian cancer has attracted much attention, especially in the treatment of MDR in ovarian cancer. In this review, the mechanism of TP on ovarian cancer is reviewed in the two aspects of inhibiting the proliferation and inducing the apoptosis of tumor cells. The toxicity of TP and the short half-life have limited the clinical application. However,the emergence of nano-drug delivery technology has provided a broader prospect for the treatment of ovarian cancer by TP.